Discontinued — last reported Q2 '24
ResMed Sleep and Respiratory Care — Amortization expense increased by 15.8% to $1.22M in Q2 2024 compared to the prior quarter. Year-over-year, this metric declined by 12.9%, from $1.40M to $1.22M. Over 3 years (FY 2021 to FY 2024), Sleep and Respiratory Care — Amortization expense shows an upward trend with a 4.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels may indicate significant recent acquisitions of intellectual property or technology portfolios.
The periodic expense recognized for the reduction in value of intangible assets, such as patents and acquired technology...
Common for companies with significant R&D or M&A activity; peers report this as part of 'Amortization of Intangibles'.
rmd_segment_sleep_and_respiratory_care_amortization_expense| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $900.00K | $900.00K | $1.07M | $1.07M | $1.06M | $1.23M | $1.34M | $1.37M | $1.40M | $1.92M | $1.32M | $1.05M | $1.22M |
| QoQ Change | — | +0.0% | +19.1% | -0.1% | -0.8% | +15.6% | +9.4% | +1.8% | +2.6% | +36.7% | -30.9% | -20.4% | +15.8% |
| YoY Change | — | — | — | — | +18.0% | +36.4% | +25.3% | +27.6% | +32.0% | +56.0% | -1.4% | -22.9% | -12.9% |